Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT01781715

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01781715
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Russia (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01781715. Randomized; no masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2013-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI
Acronym
ZES for STEMI
Condition
ST Elevation Myocardial Infarction, Multivessel Coronary Artery Disease
Intervention (Device)
Zotarolimus-eluting coronary stent
Lead sponsor
Russian Academy of Medical Sciences (class: other)
Collaborator
Medtronic (class: industry)

Record details

Record id
cardio:ct-nct01781715
Content hash
c7b4c2f45ba1a90d8adebe6ead2881b2efa7918be29c83f59fb4209bde8c4f58